Pharmaceutical Scotland-based specialty drugmaker ProStrakan Group (LSE: PSK) and Canada's Paladin Labs say that they plan to enter into a new strategic relationship in which Paladin will acquire, by way of assignment, ProStrakan's existing secured debt facility, with the addition of certain conversion rights, and will be granted an exclusive licence to ProStrakan's products for certain emerging territories. 20 December 2010